Inherited Retinal Disease Market Report 2025

This Inherited Retinal Disease market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The inherited retinal disease market size has grown strongly in recent years. It will grow from $11.56 billion in 2024 to $12.58 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth during the historic period can be attributed to the adoption of gene therapy, regulatory incentives, an increase in patient registries, the rise in clinical trials, and the growing focus on patient-centric solutions.

The inherited retinal disease market size is expected to see strong growth in the next few years. It will grow to $17.42 billion in 2029 at a compound annual growth rate (CAGR) of 8.5%. In the forecast period, growth is expected to be driven by the increased use of CRISPR, the emergence of personalized treatments, advancements in regenerative medicine, the growth of patient advocacy, and a focus on improving patients' quality of life. Key trends in the forecast period include advancements in optogenetics technology, the development of artificial retina implants, the expansion of digital health platforms, the integration of artificial intelligence in disease modeling, and the use of artificial intelligence in treatment planning.

The increasing prevalence of macular degeneration is expected to drive the growth of the inherited retinal disease market. Macular degeneration, an age-related eye condition that damages the macula, results in central vision loss and challenges with activities such as reading or recognizing faces. The rising incidence of macular degeneration is driven by factors such as aging populations, longer life expectancy, and lifestyle choices such as smoking and poor nutrition, which elevate the risk. Inherited retinal disease treatments target the genetic causes of retinal degeneration, offering therapies that can slow disease progression, restore lost vision, or prevent further damage to the retina. This ultimately improves visual outcomes and quality of life for those affected by age-related or inherited forms of macular degeneration. For example, in February 2024, the Canadian Ophthalmological Society reported that 2.5 million Canadians over the age of 55 suffer from vision loss due to age-related macular degeneration (AMD). The increasing prevalence of macular degeneration is thus fueling market growth in the inherited retinal disease sector.

Companies in the inherited retinal disease market are focusing on innovative treatments, such as mutation-agnostic gene therapy, to address a broader range of genetic variations associated with these conditions. Mutation-agnostic gene therapy targets general genetic mechanisms or pathways rather than specific mutations, making it applicable to a wider variety of genetic disorders. For example, in March 2024, Nanoscope Therapeutics Inc., a U.S.-based biotechnology company, announced positive results from a clinical trial of its lead program, MCO-010, which demonstrated vision improvements for patients with severe, permanent vision loss from advanced retinitis pigmentosa. MCO-010 achieved both primary and key secondary endpoints with statistical significance and no serious adverse events.

In October 2024, Ocuphire Pharma, Inc., a U.S.-based biopharmaceutical company, acquired Opus Genetics Inc. for an undisclosed amount. This acquisition aimed to strengthen Ocuphire Pharma's gene therapy portfolio and expedite the development of treatments for inherited retinal diseases (IRDs) by integrating Opus Genetics Inc.'s innovative gene therapies for rare retinal conditions. Opus Genetics Inc. is a clinical-stage company focused on advancing gene therapies for inherited retinal diseases.

Major players in the inherited retinal disease market are Johnson & Johnson, Novartis AG, Astellas Pharma Inc., Biogen Inc., Vertex Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Invitae Corporation, Spark Therapeutics, Aldeyra Therapeutics, Regenxbio Inc., IVERIC bio, MeiraGTx Limited, Ocugen Inc., Coave Therapeutics, Bionic Vision Technologies, GenSight Biologics SA, LKC Technologies Inc., Sparing Vision, ProQR Therapeutics NV, Endogena Therapeutics.

North America was the largest region in the inherited retinal disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inherited retinal disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the inherited retinal disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Inherited retinal diseases are a group of rare genetic disorders caused by mutations in specific genes, primarily affecting the retina, the light-sensitive tissue at the back of the eye. These diseases are often challenging to treat due to their genetic complexity, but advancements in gene therapy and other innovative technologies offer promising treatment options.

The main approaches for treating inherited retinal diseases include diagnosis and therapy. Diagnosis utilizes advanced technologies such as genetic testing, optical coherence tomography, and fundus imaging to identify these diseases and determine their genetic causes. These treatments address various conditions such as retinitis pigmentosa, choroideremia, Stargardt disease, cone-rod dystrophy, Leber congenital amaurosis, and others. They are distributed through channels such as retail sales and direct tenders, and are used by various end users including hospitals, specialty clinics, ambulatory surgical centers, home healthcare settings, and others.

The inherited retinal disease market research report is one of a series of new reports that provides inherited retinal disease market statistics, including inherited retinal disease industry global market size, regional shares, competitors with a inherited retinal disease market share, detailed inherited retinal disease market segments, market trends and opportunities, and any further data you may need to thrive in the inherited retinal disease industry. This inherited retinal disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The inherited retinal disease market includes revenues earned by entities by providing services such as ophthalmic tests, optic nerve imaging, and electrophysiological tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.